XML 39 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Payments - 2017 Share Incentive Plan (Details) - 2017 Share Incentive Plan - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jul. 26, 2017
Jun. 30, 2018
Jun. 30, 2018
Options      
Outstanding at beginning of year (in shares)     294,100
Granted (in shares)     1,717,400
Forfeited (in shares)     (42,000)
Outstanding at end of year (in shares)   1,969,500 1,969,500
Weighted average exercise price in $ per share      
Outstanding balance at beginning of year (in dollars per share)     $ 6.92
Granted (in dollars per share)     6.04
Forfeited (in dollars per share)     6.92
Outstanding balance at end of year (in dollars per share)   $ 6.16 $ 6.16
Stock-Based Compensation Expense      
Share-based compensation expense   $ 300 $ 700
Options      
Share-Based Payments      
Vesting period     10 years
Stock-Based Compensation Expense      
Weighted-average grant date fair value (in dollars per share)     $ 3.51
Fair Value Assumptions      
Expected term of options (in years)     6 years
Dividend yield (as a percent)     0.00%
Weighted-average remaining contractual life     9 years 7 months 6 days
Unrecognized compensation expense      
Total unrecognized compensation related to non-vested options (in dollars)   $ 6,300 $ 6,300
Period of recognition of total unrecognized compensation related to options     1 year 7 months 6 days
Options | Minimum      
Fair Value Assumptions      
Expected volatility (as a percent)     60.00%
Risk-free interest rate (as a percent)     2.60%
Term of U.S. treasury securities used to estimate risk free interest rate     5 years
Options | Maximum      
Fair Value Assumptions      
Expected volatility (as a percent)     61.00%
Risk-free interest rate (as a percent)     2.90%
Term of U.S. treasury securities used to estimate risk free interest rate     7 years
SARs      
Share-Based Payments      
Vesting period     10 years
Restricted Stock Units      
Share-Based Payments      
Number of shares outstanding   328,300 328,300
Expiration period if drug is not approved     2 years
Restricted Stock Units      
Granted during the period     339,550
Grant date fair value per share     $ 6.47
Restricted Stock Units | Immediate vesting upon regulatory approval      
Restricted Stock Units      
Percentage that vests during the period     50.00%
Restricted Stock Units | Vesting upon the one-year-anniversary of FDA approval      
Share-Based Payments      
Vesting period     1 year
Restricted Stock Units      
Percentage that vests during the period     50.00%
Restricted Stock Units | Chief Executive Officer      
Options      
Granted (in shares)     67,500
Stock-Based Compensation Expense      
Share-based compensation expense     $ 0
Ordinary Shares      
Share-Based Payments      
Number of shares authorized 3,000,000    
Additional shares authorized 3,438,990    
Shares available for grant   4,980,271 4,980,271
Ordinary Shares | Minimum      
Share-Based Payments      
Annual increase, to be added on the first day of each fiscal year (in shares) 2,000,000    
Annual increase, to be added on the first day of each fiscal year (as a percent) 4.00%